RNS Number : 9805O
Immupharma PLC
05 June 2020
 

RNS: FOR IMMEDIATE RELEASE                                                                                                                         5 June 2020

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Notification of Change of Registered Office Address

 

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 ("MAR").

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

 

Degroof Petercam (Liquidity Provider)

Erik De Clippel

 

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60

 

 

+32 (0) 2 287 95 34

 

 

 

+32 (0) 477 504 784

+32 (0) 475 903 909

 

 

 

 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CROEANKLESAEEEA ]]>